Optimise your Phase II trial before enrolling a single patient.

Simulate different doses, patient populations and trial designs across virtual patients to identify the designs with the best chance of success. Now available for NSCLC and PD-1 / PD-L1 inhibitors.

Talk to us

Work with us

We’re partnering with a small number of oncology teams to test Causomic on real Phase II programs.

01

Model your compound

Bring your compound and relevant clinical data.

02

Run virtual Phase II trials

Simulate your trial across thousands of virtual patients.

03

Compare & optimise designs

Explore different trial designs and identify the most promising approach.

Talk to us

Start from a model calibrated to your compound

Start with the compound, its mechanism of action, preclinical data, Phase I PK/PD, and indication. We build a model that matches the observed data, then simulate the compound across virtual patients.

Illustrative calibration on simulated data.

Test protocols across realistic patient populations

Simulate each protocol across thousands of virtual patients, varying eligibility criteria, biomarkers and patient characteristics to understand how each design performs across realistic populations.

Protocols · Virtual patients · Simulated outcomes

Illustrative NSCLC cohort. These are simulation outputs, not results from a clinical trial.

Find the trial design with the best chance of success

Explore and compare thousands of possible Phase II designs across the same virtual population, before enrolling a single patient.

Simulated Trial Designs Simulated design Top-ranked design
Selecting design partners · NSCLC · PD-1 / PD-L1

Work with us

We’re partnering with a small number of teams to test Causomic on real Phase II programs and shape what comes next.

Talk to us
Causomic. Virtual clinical development. hello@causomic.com © 2026